Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1992 2
1993 2
1994 2
1995 4
1996 1
1997 4
1998 5
1999 8
2000 1
2001 4
2002 1
2003 2
2004 1
2006 2
2008 2
2009 4
2010 2
2011 7
2012 13
2013 15
2014 14
2015 11
2016 6
2017 4
2018 6
2019 1
2020 5
2021 11
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

135 results
Results by year
Filters applied: . Clear all
Page 1
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Cohen SB, et al. Among authors: wollenhaupt j. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. RMD Open. 2020. PMID: 33127856 Free PMC article. Clinical Trial.
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S. Wollenhaupt J, et al. Arthritis Res Ther. 2019 Apr 5;21(1):89. doi: 10.1186/s13075-019-1866-2. Arthritis Res Ther. 2019. PMID: 30953540 Free PMC article. Clinical Trial.
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
Günther S, Reinke PYA, Fernández-García Y, Lieske J, Lane TJ, Ginn HM, Koua FHM, Ehrt C, Ewert W, Oberthuer D, Yefanov O, Meier S, Lorenzen K, Krichel B, Kopicki JD, Gelisio L, Brehm W, Dunkel I, Seychell B, Gieseler H, Norton-Baker B, Escudero-Pérez B, Domaracky M, Saouane S, Tolstikova A, White TA, Hänle A, Groessler M, Fleckenstein H, Trost F, Galchenkova M, Gevorkov Y, Li C, Awel S, Peck A, Barthelmess M, Schlünzen F, Lourdu Xavier P, Werner N, Andaleeb H, Ullah N, Falke S, Srinivasan V, França BA, Schwinzer M, Brognaro H, Rogers C, Melo D, Zaitseva-Doyle JJ, Knoska J, Peña-Murillo GE, Mashhour AR, Hennicke V, Fischer P, Hakanpää J, Meyer J, Gribbon P, Ellinger B, Kuzikov M, Wolf M, Beccari AR, Bourenkov G, von Stetten D, Pompidor G, Bento I, Panneerselvam S, Karpics I, Schneider TR, Garcia-Alai MM, Niebling S, Günther C, Schmidt C, Schubert R, Han H, Boger J, Monteiro DCF, Zhang L, Sun X, Pletzer-Zelgert J, Wollenhaupt J, Feiler CG, Weiss MS, Schulz EC, Mehrabi P, Karničar K, Usenik A, Loboda J, Tidow H, Chari A, Hilgenfeld R, Uetrecht C, Cox R, Zaliani A, Beck T, Rarey M, Günther S, Turk D, Hinrichs W, Chapman HN, Pearson AR, Betzel C, Meents A. Günther S, et al. Among authors: wollenhaupt j. Science. 2021 May 7;372(6542):642-646. doi: 10.1126/science.abf7945. Epub 2021 Apr 2. Science. 2021. PMID: 33811162 Free PMC article.
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C; ORAL Step investigators. Burmester GR, et al. Among authors: wollenhaupt j. Lancet. 2013 Feb 9;381(9865):451-60. doi: 10.1016/S0140-6736(12)61424-X. Epub 2013 Jan 5. Lancet. 2013. PMID: 23294500 Clinical Trial.
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D. Mease PJ, et al. Among authors: wollenhaupt j. Ann Rheum Dis. 2014 Jan;73(1):48-55. doi: 10.1136/annrheumdis-2013-203696. Epub 2013 Aug 13. Ann Rheum Dis. 2014. PMID: 23942868 Free PMC article. Clinical Trial.
[Rheumatism in elderly patients].
Wollenhaupt J, Zink A. Wollenhaupt J, et al. Z Rheumatol. 2014 Apr;73(3):215-6. doi: 10.1007/s00393-013-1241-7. Z Rheumatol. 2014. PMID: 27039909 German. No abstract available.
[Emergencies in rheumatology].
Wollenhaupt J, Swoboda B. Wollenhaupt J, et al. Z Rheumatol. 2012 Jun;71(4):260. doi: 10.1007/s00393-011-0912-5. Z Rheumatol. 2012. PMID: 22699214 German. No abstract available.
[Rheumatology training positions in Germany].
Pfeil A, Krusche M, Proft F, Vossen D, Braun J, Baraliakos X, Berliner MN, Keyßer G, Krause A, Lorenz HM, Manger B, Schuch F, Specker C, Wollenhaupt J, Voormann A, Fleck M. Pfeil A, et al. Among authors: wollenhaupt j. Z Rheumatol. 2022 Oct 20. doi: 10.1007/s00393-022-01284-4. Online ahead of print. Z Rheumatol. 2022. PMID: 36264331 German.
[Spondylarthritis].
Köhler L, Wollenhaupt J, Zeidler H. Köhler L, et al. Among authors: wollenhaupt j. Fortschr Med. 1999 Mar 30;117(9):34-6. Fortschr Med. 1999. PMID: 10231996 German. No abstract available.
135 results